CDTX

Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024

Retrieved on: 
Friday, April 26, 2024
Infection, ESCMID, Johnson & Johnson, CDTX, DFC, Therapy, Patient, Half-life, SAN, Pharmaceutical industry

The first presentation highlights data from the Phase 2a study of CD388, showing the DFC was well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challenged with influenza.

Key Points: 
  • The first presentation highlights data from the Phase 2a study of CD388, showing the DFC was well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challenged with influenza.
  • The second presentation highlights data from a Phase 1 single ascending dose study of CD388 which showed the drug has an extended half-life of 6-8 weeks.
  • These data underscore the potential of CD388 to provide patients with seasonal influenza prevention.
  • “Data presentations at the ESCMID 2024 conference support our belief that CD388 has the potential to provide season-long, universal protection from influenza,” said Jeffrey Stein, Ph.D., President and Chief Executive Officer of Cidara.

CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, April 26, 2024
P.C, Bank statement, CDTX, News, Therapy, Telephone

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cidara Therapeutics, Inc. (“Cidara Therapeutics” or the “Company”) (NASDAQ: CDTX) on behalf of Cidara Therapeutics stockholders.

Key Points: 
  • NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cidara Therapeutics, Inc. (“Cidara Therapeutics” or the “Company”) (NASDAQ: CDTX) on behalf of Cidara Therapeutics stockholders.
  • Our investigation concerns whether Cidara Therapeutics has violated the federal securities laws and/or engaged in other unlawful business practices.
  • On April 16, 2024, Cidara Therapeutics filed a current report on Form 8-K with the SEC.
  • ]”
    On this news, the price of Cidara Therapeutics stock fell by $1.89 per share, or 11.46%, to close at $14.60 on April 16, 2024.

Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline

Retrieved on: 
Wednesday, April 24, 2024
Melinta Therapeutics, Sale, Tavarua, Health care, IND, Disease, CDTX, Patent, Patient, CMC, Asset, Intellectual property, DFC, Therapy, SAN, Respect, Pharmaceutical industry

Mundipharma currently has commercial rights to rezafungin outside the U.S. and Japan.

Key Points: 
  • Mundipharma currently has commercial rights to rezafungin outside the U.S. and Japan.
  • Mundipharma purchased the assets in consideration of its assumption of the ongoing obligation to conduct and fund the ReSPECT Phase 3 clinical trial, the costs of the rezafungin patent portfolio and CMC and regulatory obligations.
  • The purchased assets also include all rezafungin intellectual property rights, product data, regulatory approvals, rezafungin product and comparator inventory, specified prepaid assets and specified contracts.
  • *Assets and rights acquired by Napp Pharmaceutical Group Limited, a member of the international network of Mundipharma independent associated companies.

Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million

Retrieved on: 
Wednesday, April 24, 2024
Doctor of Philosophy, Sale, Tavarua, Safety, Johnson & Johnson, Vaccine, CDTX, Patient, Acquisition, BVF, DFC, Therapy, SAN, Pharmaceutical industry

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that it has entered into a definitive agreement with Johnson & Johnson1 to reacquire the exclusive global development and commercial rights to CD388, which is in development for the prevention of all strains of influenza A and B.

Key Points: 
  • The proceeds from the private placement fund the upfront payment under the agreement with Johnson & Johnson and are expected to provide runway beyond topline data from CD388’s Phase 2b trial.
  • CD388 is a long-acting antiviral investigational drug invented and developed by Cidara that became the subject of an exclusive worldwide license and collaboration agreement established with Johnson & Johnson in April 2021.
  • In exchange for reacquiring the exclusive global development and commercial rights to CD388, Johnson & Johnson has received from Cidara a one-time upfront payment of $85 million and is eligible to receive potential additional development, regulatory, and commercial milestone payments.
  • “We have followed the development of CD388 over time with great interest,” said Dr. Tadvalkar.

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, April 22, 2024
CD73, Research, IND, Form, IO, AACR, Fungemia, Immunotherapy, Congress, Annual report, ESMO, Janssen, Tax, DFC, Therapy, SAN, Tavarua, Safety, Annual general meeting, SITC, Collaboration, Caspofungin, Society, Workplace, European, The San Diego Union-Tribune, CDTX, Patient, Bank statement, Pharmaceutical industry

“2023 included significant accomplishments throughout our business within both our Cloudbreak® drug-Fc conjugate (DFC) and our REZZAYO® (rezafungin) programs,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.

Key Points: 
  • “2023 included significant accomplishments throughout our business within both our Cloudbreak® drug-Fc conjugate (DFC) and our REZZAYO® (rezafungin) programs,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
  • Presented at IDWeek 2023: In October 2023, Cidara presented new preclinical and clinical data on Novel Cloudbreak Influenza Drug-Fc Conjugate CD388 at IDWeek 2023.
  • Net loss for the three months ended December 31, 2023 was $3.2 million, compared to a net loss of $13.6 million for the three months ended December 31, 2022.
  • Net loss for the full year ended December 31, 2023 was $22.9 million, compared to a net loss of $33.6 million for the year ended December 31, 2022.

Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice

Retrieved on: 
Monday, April 22, 2024
Annual report, Security (finance), File, Form, CDTX, Patient, Panel, Failure, DFC, Therapy, Letter, SAN

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced on April 17, 2024, that the Company received a notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) advising the Company that its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the Form 10-K) with the Securities and Exchange Commission (the SEC), in contravention of Nasdaq Listing Rule 5250(c)(1) (the Filing Requirement), could serve as an additional deficiency and basis for the delisting of the Company’s securities from Nasdaq.

Key Points: 
  • SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced on April 17, 2024, that the Company received a notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) advising the Company that its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the Form 10-K) with the Securities and Exchange Commission (the SEC), in contravention of Nasdaq Listing Rule 5250(c)(1) (the Filing Requirement), could serve as an additional deficiency and basis for the delisting of the Company’s securities from Nasdaq.
  • The Company was provided with the opportunity and plans to timely submit its plan to evidence compliance with the Filing Requirement for consideration by the Nasdaq Hearings Panel (the Panel)  indicating that the Company filed the Form 10-K with the SEC on April 22, 2024, and as announced on April 22, 2024, will implement a reverse stock split of its common stock at a ratio of 1-for-20 shares effective for marketplace purposes with the open of business on Wednesday, April 24, 2024.
  • As previously disclosed, by letter dated February 8, 2024, the Panel granted the Company’s request for continued listing on Nasdaq, subject to the Company regaining compliance with Nasdaq’s $1.00 bid price requirement by May 7, 2024.

Cidara Therapeutics Announces Reverse Stock Split

Retrieved on: 
Monday, April 22, 2024
Equiniti, Exercise, CDTX, Patient, CUSIP, DFC, Therapy, SAN, Security (finance)

The reverse stock split reduces the number of shares of common stock issuable upon the conversion of the Company’s outstanding shares of preferred stock and the exercise or vesting of its outstanding stock options, restricted stock units and warrants in proportion to the ratio of the reverse stock split and causes a proportionate increase in the conversion and exercise prices of such preferred stock, stock options and warrants.

Key Points: 
  • The reverse stock split reduces the number of shares of common stock issuable upon the conversion of the Company’s outstanding shares of preferred stock and the exercise or vesting of its outstanding stock options, restricted stock units and warrants in proportion to the ratio of the reverse stock split and causes a proportionate increase in the conversion and exercise prices of such preferred stock, stock options and warrants.
  • No fractional shares of common stock will be issued as a result of the reverse stock split.
  • The reverse stock split impacts all holders of the Company’s common stock proportionally and will not impact any stockholder’s percentage ownership of the Company common stock (except to the extent the reverse stock split results in any stockholder owing only a fractional share).
  • Stockholders owning shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split and will not be required to take further action in connection with the reverse stock split, subject to brokers’ particular processes.

CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX

Retrieved on: 
Thursday, April 25, 2024
Class Action Lawsuit, Professional Services, Legal, Titan, News, Advertising, CDTX, Bank statement, Therapy, Cryptocurrency

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=24442 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=24442 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Friday, April 5, 2024
CDTX, Colorectal cancer, Drug, Adenosine, Patient, SAN, Tavarua, AACR, Therapy, Cancer, Pathology, CCR5, CD73, DFC, San Diego Convention Center, Oleclumab, Escape Room, Vaccine

SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced the company will deliver four poster presentations, including one late-breaking poster presentation, at this year’s American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 at the San Diego Convention Center in San Diego, California. The presentations highlight data on the company’s multispecific CD73/PD-1 drug Fc-conjugate (DFC), its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73.

Key Points: 
  • The presentations highlight data on the company’s multispecific CD73/PD-1 drug Fc-conjugate (DFC), its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73.
  • “Our Cloudbreak platform has quickly produced DFC candidates effective in preclinical studies across various cancers with specific disease targets.
  • This week, we are sharing data on our CCR5 DFC program for the first time, which has demonstrated robust efficacy as a monotherapy in mouse models of colorectal cancer.
  • Targeting CCR5 has the potential to improve response rates to immune checkpoint inhibitor therapies, which could have a greater impact for patients unresponsive to these current treatment options.

Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Wednesday, March 6, 2024
SAN, CDTX, AACR, Therapy, Abstract, Patient, Drug, San Diego Convention Center, DFC, Colorectal cancer, CCR5

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will be presenting three abstracts and one late-breaking abstract during the American Association for Cancer Research (AACR) Annual Meeting to be held April 5-10, 2024 at the San Diego Convention Center in San Diego, California.

Key Points: 
  • SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will be presenting three abstracts and one late-breaking abstract during the American Association for Cancer Research (AACR) Annual Meeting to be held April 5-10, 2024 at the San Diego Convention Center in San Diego, California.
  • Presentation details are summarized below:
    Abstract Title: CCR5-001, a novel Drug Fc-Conjugate (DFC) targeting CCR5, demonstrates potent efficacy in a colorectal cancer mouse model
    Presenters: Elizabeth Abelovski and Nicholas Dedeic, Ph.D.